Formosa Pharmaceuticals, Inc. (TPE:6838)
Taiwan · Delayed Price · Currency is TWD 30.50
-1.20 (-3.79%)
At close: Apr 17, 2026
Formosa Pharmaceuticals Revenue
In the year 2025, Formosa Pharmaceuticals had annual revenue of 9.50M TWD, down -93.38%. Formosa Pharmaceuticals had revenue of 3.23M in the quarter ending December 31, 2025, a decrease of -45.28%.
Revenue
9.50M
Revenue Growth
-93.38%
P/S Ratio
484.97
Revenue / Employee
n/a
Employees
n/a
Market Cap
4.60B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 9.50M | -133.86M | -93.38% |
| Dec 31, 2024 | 143.36M | 112.18M | 359.89% |
| Dec 31, 2023 | 31.17M | 29.86M | 2,270.49% |
| Dec 31, 2022 | 1.32M | -27.21M | -95.39% |
| Dec 31, 2021 | 28.53M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Panion & Bf Biotech | 2.06B |
| Medigen Biotechnology | 1.58B |
| Sagittarius Life Science | 346.08M |
| BioGend Therapeutics | 222.34M |
| Pharmosa Biopharm | 67.27M |
| OBI Pharma | 58.58M |
| ACRO Biomedical | 36.50M |
| UnicoCell Biomed | 30.10M |